Colorectal cancer screening

Colorectal cancer screening saves lives. There are many tests available to help detect this type cancer. Colorectal cancer is generally more treatable when it is found early, before it has a chance to spread. In fact, the American Cancer Society reports the five-year survival rate is about 90 percent.

Screening is vitally important. But because many men and women are not tested, only about four out of 10 are diagnosed at an early stage when treatment is most likely to be successful. The Centers for Disease Control and Prevention reports that if everyone aged 50 years or older were screened regularly, as many as 60 percent of deaths from this cancer could be avoided. More than 140,000 Americans are diagnosed with colorectal cancer, and more than 50,000 people die from it every year.

Due to the educational efforts of cancer support groups and government agencies, there is help and hope. According to the American Cancer Society, more than a million people in the U.S. count themselves as survivors of colorectal cancer.

Contact your Cardinal Health sales representative for information about these products that help with the detection and screening of colorectal cancer.

Beckman Coulter® — Hemoccult® ICT test

Detect human hemoglobin from blood in fecal samples with this rapid, qualitative immunochemical fecal occult blood test. The Hemoccult® ICT test offers significant benefits over traditional guaiac paper tests. It is specific to human hemoglobin, which results in fewer false positive readings. An increased specificity to lower GI bleeding makes it an ideal tool to screen for colorectal cancer.

The test also helps eliminate the need for diet and drug restrictions, which makes it easier for patients to comply with the test. The safe and noninvasive test can be performed in a physician's office or at the patient's home. Results are clear and easy-to-read. CLIA-waived. Controls are also available separately.

Beckman Coulter, the stylized logo and Hemoccult are trademarks of Beckman Coulter, Inc. and are registered in the USPTO.

Beckman Coulter® — Hemoccult® ICT test literature

Beckman Coulter® — Hemoccult® SENSA slide test

This paper slide test is used for the enhanced detection of fecal occult blood. It includes the on-slide performance monitor feature to check the function and stability of each slide. Sensitive test is indicated to detect fecal occult blood. It is particularly useful as an aid in early detection of asymptomatic gastrointestinal conditions, including colorectal cancer. Test is easy-to-use and provides results within 60 seconds. Single-slide configuration includes applicators and developer solution. Stable for 36 months from date of manufacture when stored as directed.

Beckman Coulter, the stylized logo, Hemoccult and SENSA are trademarks of Beckman Coulter, Inc. and are registered in the USPTO.

Beckman Coulter® Hemoccult® SENSA slide test literature
1.5 Mb - PDF

Hemosure® — iFOB test

Hemosure® iFOB tests are specifically designed for colorectal cancer screening. Clinicians can expect higher patient compliance due to no dietary or drug restrictions. Compared to guaiac testing, the test is more sanitary and user-friendly. Also provides higher specificity, sensitivity and accuracy as compared to the traditional guaiac test. T1-CK30 is ideal for use in a doctor's office, while T1-CK30T and T1-CK50 are excellent for use in a laboratory setting.

Hemosure® — iFOB test literature

Quidel® — QuickVue® iFOB test

The QuickVue® iFOB test is intended for the qualitative detection of fecal occult blood with results available in 5 to 10 minutes. Designed to be more sensitive than traditional guaiac-based methods, it has no dietary restrictions and requires only one specimen collection from the patient. It offers analytical sensitivity of 50ng hHb/mL buffer or 50μg hHb/g feces specific to human hemoglobin. The specimen collection tube doubles as a convenient/sanitary dispenser.

Kits can be stored at room temperature for 24 months from date of manufacture. External controls (positive and negative) are also available separately. CLIA-waived.

Quidel® — QuickVue® iFOB test literature

Immunostics — Hema-Screen Stat™ Slide test

Hema-Screen Stat™ is a self-contained testing format with the developer directly attached to the slide. It is released by pulling the patented DEVEL-A-TAB™. This one-step format provides simplicity, reliability and includes an on-slide control. Hema-Screen Stat™ reacts positively to hemoglobin levels of 2mg/mL with the Hema-Screen Stat™ test. Kit includes 50 two-hole slides with on-slide control and built-in developer and 50 applicators. Test is designed to help eliminate:

  • Losing bottles of developer
  • Counting drops
  • Cross-contamination
  • Exposure to hazardous chemicals
  • Cross-checking lot numbers on slides and developer

Aerscher Diagnostics — HemaPrompt™ FG Gastric and Fecal Occult Blood tests

This guaiac-based in vitro slide test can be used to detect fecal occult blood in feces and gastric aspirate or vomitus. The developer solution is built-in to each slide, so there is no developer bottle to misplace or misuse. The test is portable and helps you avoid cross-contamination. Each slide is also equipped with internal controls to monitor the effectiveness of the chemicals and the test. Test is sensitive to 100μg hemoglobin/mL gastric juice and 2mg hemoglobin/g stool. Results can be read from the card through a clear plastic window after 60 seconds. Slides should be stored at room temperature (from 10° to 22°C) and should be protected from heat, sunlight, fluorescent light, UV radiation, humidity, volatile chemicals and gases. Do not refrigerate or freeze. Slides are stable until expiration date. 50 tests per box.

Aerscher HemaPrompt™ FG literature
207 Kb - PDF

Sources:
 

  1. National Cancer Institute, http://www.cancer.gov/cancertopics/factsheet/detection/colorectal-screening
  2. Centers for Disease Control and Prevention, http://www.cdc.gov/features/colorectalawareness
  3. American Cancer Society, http://www.cancer.org/cancer/colonandrectumcancer/index